{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-005116","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2024-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.084387+00:00","generated_at":"2026-05-31T05:49:54.922402+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cassava Sciences appoints Rick Barry as CEO; Claude Nicaise becomes Chairman","bullets":["Richard Barry named CEO effective September 6, 2024; previously Executive Chairman and director since June 2021.","Board separates CEO and Chairman roles; Claude Nicaise, M.D. appointed Chairman.","Dr. Nicaise served as director since Dec 2023; held regulatory roles at Alexion and Bristol-Myers Squibb.","First Phase 3 trial of simufilam (n=804) topline expected by end of 2024; second Phase 3 (n=1,125) by mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-005116","json":"https://secwatch.observer/filing/0001171843-24-005116.json","markdown":"https://secwatch.observer/filing/0001171843-24-005116.md","text":"https://secwatch.observer/filing/0001171843-24-005116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324005116/0001171843-24-005116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324005116/f8k_090924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:49:54.922402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"710db9ab40","claim":"Richard (Rick) Barry was appointed as Chief Executive Officer at FILANA THERAPEUTICS, INC..","evidence_excerpt":"On September 9, 2024, Cassava Sciences, Inc. (“Cassava” or the “Company”) announced that the Company’s Board of Directors has concluded its search for a Chief Executive Officer (“CEO”) and has appointed Richard (Rick) Barry as the Company’s CEO.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324005116/0001171843-24-005116-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ed2503a1ae","claim":"Claude Nicaise was appointed as Chairman at FILANA THERAPEUTICS, INC..","evidence_excerpt":"the Board has appointed Claude Nicaise, M.D., as its Chairman.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324005116/0001171843-24-005116-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}